AlphAIAlphAI — Financial news for AI agents
tradingview.com$CRMD

Key facts: CorMedix to Acquire Heron’s Four Commercial Assets for $145M, Shares and Earn-Outs

CorMedix (CRMD) will acquire four commercial products from Heron Therapeutics for $145M in cash, 14.6M shares, and up to $55M in earn-outs. The deal, expected to close in Q1 2027, includes therapies for post-surgery pain, nausea, and chemotherapy-related nausea. CorMedix plans to sell these products through its existing network.

Original reporting
tradingview.com
Published Nov 10, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 8:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Key facts: CorMedix to Acquire Heron’s Four Commercial Assets for $145M, Shares and Earn-Outs — source image
Source · tradingview.com
Decision brief

The 30-second read

$CRMDBullishMed
01

Why it matters

The transaction expands CorMedix's commercial pipeline and may accelerate revenue growth, but integration risk remains.

02

Market read

First disclosure of a $145M acquisition, providing a fresh catalyst for CorMedix's stock.

03

What to watch

Regulatory approval risk for the acquired therapies and potential competition

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

CorMedix is a clinical‑stage biotech focused on pain and nausea treatments; Heron Therapeutics holds four marketed products in these areas.

Company-level read

Ticker impact

$CRMDBullishHigh confidence
Context

CorMedix announced it will acquire Heron Therapeutics' four commercial assets for $145M cash, 14.6M shares and up to $55M in earn‑outs.

Expected impact

likely upward pressure as investors price in the deal's growth potential

Evidence & confidence

Deal size is material for a biotech of this scale and the cash‑plus‑stock consideration signals confidence in the assets.

Market effects

Sector

strengthens the biotech sector's M&A activity and may boost related pain‑management stocks

Regional

U.S. biotech market may see modest uplift

Global

limited to investors tracking specialty pharma acquisitions

Counterpoint

What could challenge this read

Deal could dilute existing shareholders if integration costs exceed expectations

Key entities

  • Company
    CorMedix

    Acquirer, US‑listed biotech

  • Company
    Heron Therapeutics

    Seller of four commercial assets

Read at source← All news

Related articles

$CRMDHighAI 8/10

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings

CorMedix (CRMD) will acquire assets from Heron, adding four products and aiming for $60M in savings. Heron may receive up to $55M in additional payments tied to ZYNRELEF's 2028 sales. CorMedix will fund the deal with $70M in cash and a $150M loan. Heron's convertible debt holders will convert debt into CorMedix stock. CorMedix plans to relaunch SUSTOL and focus on APONVIE, with a potential FDA approval for an undisclosed injectable product in 2027.

finance.yahoo.com
$CRMDHighAI 8/10

CorMedix stock maintains outperform rating on Heron acquisition

Citizens reiterated an Outperform rating and $19.00 price target on CorMedix (CRMD). The company agreed to acquire Heron Therapeutics' assets for $225M, expecting to close in Q1 2027. CRMD reported Q2 2026 earnings of $0.29/share on $101.9M revenue, beating estimates. Analysts highlight strategic fit, revenue diversification, and strong financials.

investing.com
$CRMDHighAI 9/10

CorMedix, Heron Strike $223 Mln Upfront Asset Deal; Closing Expected In 2027; Stock Up

CorMedix (CRMD) will acquire Heron's (HRTX) assets for $222.6M upfront, including cash and stock, with potential earn-outs. The deal adds four commercial-stage products to CorMedix's portfolio, expected to close in 2027. CorMedix anticipates earnings accretion and cost synergies, while Heron will remain public and evaluate future opportunities. Both stocks rose on the news.

rttnews.com
$CRMDHighAI 8/10

CorMedix stock gains as Heron deal adds four products

CorMedix (CRMD) shares rose 4.5% premarket after announcing a $222.6M deal to acquire Heron Therapeutics' (HRTX) assets, including four commercial products. CorMedix will pay $145M cash and issue 14.6M shares. The deal is expected to close in Q1 2027 and be immediately accretive to earnings, with pro forma 2026 revenue estimated at $465M-$490M.

investing.com
$HRTXMedAI 8/10

Heron Therapeutics to Sell Most Assets to CorMedix for $145 Million Cash and 14.6 Million Shares

Heron Therapeutics (HRTX) agreed to sell most of its assets to CorMedix for $145M in cash and 14.6M shares, with potential royalties and earn-outs. The deal requires shareholder approval and is expected to close in six months. Heron plans to use proceeds to repay debt and explore new opportunities. Separately, Rubric Capital can exchange $35M in convertible notes for CorMedix shares post-sale.

tradingview.com